- Talking to a Loved One Battling Substance Abuse: Staying Positive Is Key
- RSV Vaccine Given in Pregnancy to Help Shield Newborns Receives Full U.S. Approval
- Many Americans Frustrated in Search for Low-Cost COVID Boosters
- In 22 U.S. States, More Than a Third of Adults Are Now Obese
- Kraft Cheese Slices Recalled Due to Plastic Wrap Choking Hazard
- Kids’ ER Visits for Mental Health Crises Rise When School Term Begins
- Medicaid Reinstated for Nearly 500,000 Children and Families: CMS
- Newer Diabetes Meds Might Not Work as Well in Black Patients
- Vaping Raises a Teen’s Odds of Developing Asthma
- Scientists Spot Gene Mutation Linked to Esophageal Cancer
Northera Approved For Rare Blood Pressure Condition

Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.
Neurogenic orthostatic hypotension (NOH) is most often associated with Parkinson’s disease and other neurologic disorders. Symptoms may include dizziness, lightheadedness, blurred vision, fatigue and fainting, the FDA said in a news release.
Granted accelerated approval to treat a rare condition, the drug will have a boxed label warning that it could cause an unhealthy rise in blood pressure while a person is lying down. This potential side effect could lead to a stroke, the agency said, warning that Northera users should be monitored carefully.
Other less serious side effects could include headache, dizziness, nausea, high blood pressure and fatigue, the FDA said.
Northera is produced by Chelsea Therapeutics, based in Charlotte, N.C.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.